Annelot J M Meijer, Franciscus A Diepstraten, Marc Ansari, Eric Bouffet, Archie Bleyer, Brice Fresneau, James I Geller, Alwin D R Huitema, Per Kogner, Rudolf Maibach, Allison F O'Neill, Vassilios Papadakis, Kaukab M Rajput, Gareth J Veal, Michael Sullivan, Marry M van den Heuvel-Eibrink, Penelope R Brock
PURPOSE: Hearing loss occurs in 50%-70% of children treated with cisplatin. Scientific efforts have led to the recent approval of a pediatric formula of intravenous sodium thiosulfate (STS) for otoprotection by the US Food and Drug Administration, the European Medicines Agency, and the Medicines and Health Regulatory Authority in the United Kingdom. To inform stakeholders regarding the clinical utility of STS, the current review summarizes available literature on the efficacy, pharmacokinetics (PK), and safety of systemic STS to minimize cisplatin-induced hearing loss (CIHL)...
April 22, 2024: Journal of Clinical Oncology